Anthem Biosciences Limited (ANTHEM.NS)
NSE · INR · Healthcare · Biotechnology
₹837.15 (+1.81%) as of
Key statistics
- Market cap
- 471.76B
- P/E (TTM)
- 82.48
- Forward P/E
- 55.38
- EPS (TTM)
- 10.15
- Dividend yield
- 0.24%
- 52-week range
- 579.15 – 977.55
- Revenue (TTM)
- 20.07B
- Profit margin
- 28.69%
- Analyst target
- ₹920.13
- Volume
- 206.74k
About Anthem Biosciences Limited
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bengaluru, India
- Employees
- 2,282
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.